Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

NCT03712943 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Metastatic Colorectal Cancer
Colon Cancer

Interventions

DRUG: Regorafenib
DRUG: Nivolumab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

Bristol-Myers Squibb